Ginkgo biloba leaves were rarely recorded in previous herbal books. Until the 1960s, scholars at home and abroad discovered the valuable medicinal value of Ginkgo biloba leaves when developing and screening natural medicines, which made Ginkgo biloba leaves stand out and quickly rank among health care products and cosmetics. Recently, it has established its extraordinary position as a legal medicine-Ginkgo biloba has been included in the legal medicine in the newly published and officially implemented Pharmacopoeia of 2000 in China, which means that its nature and taste are sweet.
In the study of Ginkgo biloba leaves, pharmacologists are very surprised to find that a small piece of Ginkgo biloba leaves contains many components, and its pharmacological activities are beyond people's expectation, including more than 20 kinds of flavonoids, terpenoids, phenols, trace elements, vitamins and amino acids. It is no exaggeration to describe it as a miniature treasure house.
A large number of pharmacological experiments show that there are two kinds of components with important pharmacological activities in Ginkgo biloba leaves: ginkgo flavone glycosides and ginkgo terpene lactones. Their unique mechanism of action is different from some commonly used drugs for cardiovascular and cerebrovascular diseases in clinic.
First, ginkgolides can selectively inhibit platelet activating factor. Platelet activating factor (PAF) is a strong endogenous active substance in human body, which can cause platelet aggregation and thrombosis. It is an invisible killer, which can induce cardiovascular and cerebrovascular diseases, especially stroke and myocardial infarction, with high risk, and ginkgolides are the bane of PAF.
Secondly, ginkgo flavone glycosides have high ability to deal with free radicals. Ginkgo flavone glycosides have been proved to be effective in resisting and scavenging free radicals and playing a good role in delaying aging. Especially the recent information from abroad. It is believed that Ginkgo biloba leaves can be used to prevent and treat patients with early Alzheimer's disease, especially to help restore and improve memory.
Thirdly, ginkgolides and flavonoid glycosides have synergistic effect, which can dilate blood vessels, increase blood flow, improve cardiovascular and cerebrovascular circulation, and protect brain and myocardial cells under hypoxia. In addition, it can reduce triglyceride in blood, increase the content of high density lipoprotein and improve the activity of superoxide dismutase in red blood cells. Therefore, Ginkgo biloba extract preparation has good curative effect on patients with coronary heart disease, angina pectoris, hyperlipidemia, concussion, sequelae of brain injury and so on. And there are few adverse reactions in general, so it is easy to be accepted as a health care drug. Shandong Teller Pharmaceutical Co., Ltd. Shandong Teller Pharmaceutical Co., Ltd. was established in August 2002. Continuous improvement and accelerated expansion have formed a large-scale pharmaceutical enterprise integrating scientific research, production and sales. Mainly engaged in Chinese herbal medicines, proprietary Chinese medicines, Chinese herbal pieces, chemical medicines, antibiotics, biochemical medicines, medical devices and other products, planning and promoting the whole process of national agent products.
Shandong Teller Pharmaceutical Co., Ltd. has more than ten departments including investment promotion department, purchasing department, finance department, deployment department, R&D department, quality inspection department, storage department and distribution center. Established a huge sales network with Shandong as the center and radiating the whole country, with customers in more than 20 provinces and cities across the country, established long-term and stable cooperative relations with more than 700 commercial units, more than 300 hospitals and more than 3000 end customers, and formed a pharmaceutical sales company. At present, as the general distributor of Qilu Pharmaceutical, Jining, Zibo Xinhua Pharmaceutical, Shandong Xianhe Pharmaceutical, Shandong Huayang Pharmaceutical, Sishui Xierkang Pharmaceutical and other well-known manufacturers, the company has close business contacts with more than 400 manufacturers such as Shandong Kang, Dezhou Deyao, Guangzhou Luofushan and Guangxi Yuyuan, realizing a strong alliance of complementary advantages and resource sharing. In 2006, the company achieved sales of 208 million yuan, with an annual growth rate of 65,438+00%, showing a rapid development momentum. In the fierce market competition, the company never forgets its social responsibility, adheres to the business philosophy of "people-oriented, honest management", advocates the business strategy of "market-oriented, quality-centered, customer-oriented, innovative development", accurately grasps the market rules, adheres to the expansion idea of general distribution and general agent, and promotes the continuous improvement of economic and social benefits. Make greater contributions to human health and the prosperity and development of medicine. Haikou Qili Pharmaceutical Co., Ltd. Haikou Qili Pharmaceutical Co., Ltd. was established in 1998 with a registered capital of 57,765,700 yuan, total assets of1600,000 yuan and a factory area of 30,000 m2. Is a private enterprise that develops from single production to three-dimensional production, sales and scientific research. Over the past eight years, based on Hainan's policy advantages, the company has made scientific decisions, been determined to reform, pioneered and innovated, and continuously enhanced the strength of the enterprise, and achieved remarkable results, enabling the enterprise to achieve low-cost self-expansion, rapid growth in annual production and sales, and gradually formed product brands and enterprise brands, as well as various resource reserves for enterprise development.
The company has 300 employees, complete production and quality management institutions, clear responsibilities, and 49 professional technicians, including 5 senior technicians, 65,438+00 intermediate technicians and 34 junior technicians, accounting for 23% of the total employees. The company has a pharmaceutical research institute, two production bases, 265,438+0 production lines that have passed the national GMP certification, and five pharmaceutical sales companies. It is a high-tech enterprise integrating scientific research, production and marketing. Production of 6 dosage forms, nearly 200 varieties and specifications. The products are mainly Chinese and western medicine antibiotics, including cardiovascular and cerebrovascular diseases, diabetes, antivirus, cold treatment, digestive system and so on. Annual production capacity: 300 million bottles of powder injection, 80 million bottles of freeze-dried powder injection, 60 million small-volume injections, 400 million capsules, 400 million tablets and 500 tons of granules.
The company gives full play to the advantages of production capacity, talent technology, variety reserve and variety of new drugs, and cooperates with many drug sales companies and pharmaceutical enterprises to form a business model of self-production and self-marketing, and cooperative production and sales. Further expand the market share of the company's products and strengthen the company's brand advantage. In 2004, the Q series products produced by the company were rated as "the most competitive 100 famous brand in China" by the evaluation center of China News Agency.
The company strictly manages the production and quality of the enterprise, simplifies the management organization, simplifies the management process, strengthens the on-site management, improves the finished product rate and labor productivity, reduces the production cost and improves the market competitiveness of the products; At the same time, establish and improve a strict quality assurance system, strictly implement the whole production process monitoring and all-round quality inspection to ensure product quality.
The company actively promotes the technological innovation of enterprises, constantly improves the supporting work of product varieties, adjusts the product structure, and accumulates stamina for the sustainable development of enterprises. Since 2003, more than 100 new varieties with development potential and market prospect have passed the declaration and acceptance of the State Food and Drug Administration of the United States. Among them, ceftriaxone sodium tazobactam sodium for injection, cefotaxime sodium tazobactam sodium for injection, cefoperazone sodium tazobactam sodium for injection and ceftazobactam sodium for injection are the first-class new drugs in four countries, doxycycline hydrochloride for injection, cefpiramide sodium for injection, cefotaxime for injection and creatine phosphate sodium for injection are the third-class new drugs in four countries, and the rest are the fourth-class and fifth-class new drugs in the country. It is estimated that the product variety of enterprises will reach more than 200 in 2006, so that the company's product variety will maintain a strong advantage in quantity and structure.
The company was recognized as a high-tech enterprise in Hainan Province, one of the top 50 industrial enterprises in Hainan Province, one of the top 30 enterprises with the most core competitiveness in industrial economy in Hainan Province, a quality trustworthy unit in Hainan Province, and the "Best Enterprise Innovation Award" in Hainan Province, and was selected into Forbes' "China Potential 100 List" in 2005.